Respiratory disease and lower pulmonary function as risk factors for subsequent dementia: a systematic review with meta-analysis

Short title: Pulmonary function and dementia

Tom C. Russ PhD MRCPsych,^{1-4*} Mika Kivimäki FMedSci,⁵ G. David Batty DSc^{1,2,5}

¹ Alzheimer Scotland Dementia Research Centre, University of Edinburgh, UK;

² Centre for Cognitive Ageing & Cognitive Epidemiology, University of Edinburgh, UK;

³ Centre for Dementia Prevention, University of Edinburgh, UK;

⁴ Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, UK;

⁵ Department of Epidemiology and Public Health, University College, London, UK

* Correspondence to: Dr Tom C. Russ, Alzheimer Scotland Dementia Research Centre, University of Edinburgh, 7 George Square, Edinburgh, EH8 9JZ, UK

Telephone: +44 (0)131 650 4340; Email: T.C.Russ@ed.ac.uk

Contributions: TCR drafted the article and all authors revised it for critical content.

Funding: No specific funding.

Manuscript statistics: article body word count of 3377 plus an abstract of 198 words, 2 figures, 2 tables, and 2 supplementary figures.

ABSTRACT

Background: In addition to affecting the oxygen supply to the brain, pulmonary function is a marker of multiple insults throughout life (including smoking, illness, and socioeconomic deprivation). By meta-analysing existing studies, we tested the hypothesis that lower pulmonary function and respiratory illness are linked to an elevated risk of dementia.

Aims: To review the best available evidence, taken from longitudinal studies, for pulmonary function and respiratory disease as risk factors of dementia.

Method: We conducted a systematic review of longitudinal studies using PubMed until April 1st, 2019 and, where possible, pooled results in random-effects meta-analyses.

Results: We identified eleven studies relating pulmonary function to later dementia risk, and eleven studies of respiratory illness and dementia (including one which studied both). The lowest quartile of lung function measure Forced Expiratory Volume in one second (FEV₁) compared with the highest was associated with a 1.5-fold (1.51, 95%CI 0.94-2.42) increased dementia risk (N_{total}=127,710, 3 studies). Respiratory illness was also associated with increased dementia risk to a similar degree (1.54, 1.30-1.81, N_{total}=288,641, 11 studies).

Conclusions: Individuals with poor pulmonary function are at increased risk of dementia. The extent to which the association between poor pulmonary function and dementia is causal remains unclear.

Key words: Dementia, Alzheimer's disease, pulmonary function, epidemiology, life course

INTRODUCTION

The considerable public health and care burden of dementia is well documented.(1) While the age-standardised prevalence and incidence of dementia may be declining,(2-4) because of population ageing, the absolute number of people with dementia worldwide is projected to triple from approximately 44 million in 2013 to 135 million by 2050.(5) Recent studies have provided promising findings for pulmonary function as a potential modifiable risk factor for late-life dementia. Pulmonary function affects the oxygen supply to the brain. Low pulmonary function and pulmonary disease, in turn, are associated with exposure to multiple insults across the full life course – notably smoking, illness, and socioeconomic deprivation, stunting – suggesting that they may capture a number of dementia risk factors.(6, 7) As the number of studies on pulmonary function and dementia increases, we provide the first aggregation of these results by conducting a systematic review and meta-analysis of the evidence from longitudinal studies to examine the hypothesis that low pulmonary function and pulmonary disease are risk factors for later dementia.

METHODS

In accordance with the PRISMA guidelines,(8) we searched PubMed for articles reporting longitudinal (cohort) studies linking pulmonary function or respiratory illness with dementia occurrence from the inception of the database (1951) until 1st April 2019. The search strategy combined the terms dementia OR alzheimer* AND “forced expiratory volume” OR “expiratory volume” OR FEV OR “forced vital capacity” OR “vital capacity” OR FVC OR “peak expiratory flow” OR “peak flow” OR PEF OR ((pulmonary OR lung OR respiratory) AND function) OR asthma OR COPD OR “respiratory disease” or COAD or “airways disease” OR “lung disease” OR pneumonia AND longitudinal OR prospective OR cohort. We also scrutinised the reference sections of retrieved papers and searched our own files. TCR screened the search results using Covidence (<https://www.covidence.org/>) and extracted data from included articles. The review

protocol was registered with PROSPERO (<https://www.crd.york.ac.uk/prospERO/>;
CRD42019130376).

We included studies that were: published in English; had a prospective cohort study design with individual level exposure and outcome data, including an appropriate exposure comparator; examined the effect of pulmonary function or pulmonary disease; reported dementia as an outcome; and reported either estimates of relative risk (RR), odds ratios (OR), or hazard ratios (HR) with 95% CIs, or provided sufficient results to calculate these estimates.

We extracted the following information from each eligible article: name of the first author, start of the follow-up for dementia (year), study location (country), number of participants, number of dementia events, mean follow-up time, mean age of participants, proportion of women, method of dementia ascertainment, and covariates included in the adjusted models. The methodology of each study informed an assessment of risk of bias. Meta-analyses were conducted using R for Windows 3.4.0 and the metafor and forestplot packages. In preliminary analyses, heterogeneity measured by the I^2 statistic was not consistently low (range: 0-94%) and so random effects models were used.

RESULTS

Our search returned 673 articles of which 627 were discarded after review of their abstract and/or title; 46 were read in full (**Figure 1**). Of these, 25 studies were excluded (eight did not focus on pulmonary function or disease, six were cross-sectional, six did not have dementia as an outcome, two were ongoing studies and no results had been published, three articles were commentaries, and one study had no comparator) with the remaining 21 being included in further analyses. We considered the results for studies recording pulmonary function (N=11) and

respiratory illness (N=11) separately (one study reported both pulmonary function and respiratory illness).

Pulmonary function as a risk factor for dementia

We identified eleven prospective cohort studies that have been used to examine the association between pulmonary function and later dementia (**Table 1**). Mean age of participants when respiratory function was measured varied between 40 and 65 in eight studies(9-16) and was over 65 in three studies.(17-19) In these studies investigators used one of several spirometric measures as the exposure of interest (risk factor): peak expiratory flow (PEF) refers to the maximum speed of forced expiration (in litres per second); Forced Expiratory Volume (FEV) denotes the volume of air (in litres) which can be expired in a specified period of time, usually in one second (FEV₁); and Forced Vital Capacity (FVC) captures the total volume of air which can be expired. Maximal inspiration is required before each measurement and many studies allow a defined number of attempts and record the best performance. These measures of pulmonary function correlate closely with each other(14) suggesting that associations seen for one measure with dementia/cognitive impairment are likely to be replicated in the other measures.

A range of methods were used to ascertain dementia, some in combination: death certification,(10, 14, 18, 19) linkage to electronic medical records (e.g., hospital discharge records),(12, 15-17, 19, 20) and clinical assessment.(9, 11, 13, 16, 19) A number of these studies were originally instigated to investigate risk factors for cardiovascular disease(10-12, 16, 18) or the menopause(9) and then repurposed to include dementia follow-up as study participants aged; only two were specifically set up to study diseases of ageing.(13, 19) Duration of follow up ranged from 12 to 40 years.(10, 14)

Figure 2 shows two meta-analyses of studies on FEV and dementia risk – one for categories of FEV and one for a unit change. Only three studies (127,710 adults, 1905 dementia cases) compared the lowest quartile of FEV₁ with the highest quartile;(12, 14, 16) pooling these results in a meta-analysis gave a HR of 1.51 (95% CI 0.94, 1.64; P=0.092; I²=47.0%). Pooling the five studies which reported the effect of one standard deviation decrease (disadvantage) in FEV₁ resulted in a HR of 1.28 (1.03-1.60; P=0.028; I²=79.3%; N=67,505, 2280 dementia cases). One of these studies standardised FEV₁ by dividing by height²(13) but a sensitivity analysis excluding this transformation gave a similar pooled result (1.24, 0.92-1.68).(9, 11, 14, 16).

Supplementary Figure 1 shows pooled results for FVC: lowest-to-highest quartile HR 1.63 (95% CI 1.14-2.32; P=0.007; I²=49.3%; five studies, N=145,409, 2456 dementia cases);(10, 12, 14, 16, 18) per standard deviation disadvantage 1.21 (0.97-1.51; P=0.086; I²=70.7%; four studies, N=63,840, 1992 dementia cases).(9, 11, 14, 16) One study included in the latter meta-analysis reported an interaction between *APOE* status and the association between FEV/FVC and dementia which contributed to the high heterogeneity observed here; excluding this study did not affect the results of the meta-analysis but reduced the heterogeneity slightly to I²=65.1%.(11)

Supplementary Figure 2 shows the result of pooling two studies which compared dementia risk in the lowest vs highest quartiles of PEF, giving a HR of 2.21 (95% CI 1.73-2.82; P<0.001; I²=0.0%; N=50,830, 678 dementia cases);(14, 17) combining the two studies which reported the association between one standard deviation decrease in PEF and dementia gave a HR of 1.39 (1.24-1.56; P<0.001; I²=10.6%; N=49,316, 540 dementia cases).(9, 14)

Four studies could not be pooled in meta-analyses because of the manner in which the results were reported. A study of 27,387 Kaiser Permanente Northern California members, of whom 7519 developed dementia over more than 28 years follow up, concluded that poorer FEV₁ (plus

FEV₂ and VC) was associated with an increased risk of dementia (multivariable-adjusted HR per litre decrease in FEV₁ 1.13, 95% CI 1.09-1.18).(15) This finding was replicated in stratified analyses for smokers and non-smokers. Investigators in the Seven Countries Studies found that men with greater FVC were less likely to die with dementia than men with lower FVC (multivariable-adjusted hazard ratio for highest quartile [Q4] vs lowest quartile [Q1] 0.54, 95% CI 0.30-0.98) but the association observed in this study did not follow a dose-response gradient (HR, 95% CI: Q3 vs Q1 1.03, 0.63-1.68; Q2 vs Q1 0.77, 0.46-1.28).(10) An Australian study found an association between lower PEF and increased risk of subsequent hospitalisation with dementia (adjusted HR lowest vs highest tertile 1.98, 95% CI 1.42-2.75).(17) Finally, of 484 men and women from the Lothian Birth Cohort 1936, 106 adjudicated dementia diagnoses were identified from multiple sources, including face-to-face clinical assessment.(19) No robust evidence was found to suggest that FEV₁ measured at age 79 years would be associated with developing dementia (multivariable-adjusted HR per litre/second increase 1.30, 95% CI 0.74-2.30).

Respiratory disease as a risk factor for dementia

We identified eleven prospective studies in which investigators had explored the association between respiratory disease and later dementia (**Table 2**). Mean age at which disease was ascertained varied from 50.6 to 82.9 years but was over 65 years in six of the 11 studies.(21-26) Investigators identified pulmonary disease using a National Health Insurance database,(21, 22, 25, 27, 28) hospitalisation data,(24) or self-report.(16, 23, 26, 29, 30) Dementia was ascertained from the Taiwanese insurance database in five studies,(21, 22, 25, 27, 28) face-to-face assessment by a clinician in four studies,(16, 23, 24, 30), cognitive test score in one,(26) and linkage to hospital discharge and death certificate data in one.(29)

Figure 2 shows a meta-analysis of these 11 studies with a total of 288,641 individuals and 15,898 dementia cases giving a pooled HR of 1.54 (95% CI 1.30-1.81; $P < 0.001$; $I^2 = 92.4\%$). Although the study-specific estimates were heterogeneous, they all favoured risk factor status. Excluding a study which investigated the association between atopic illnesses(29) (asthma, eczema, or rhinitis – only one of which is likely to have a substantial effect on pulmonary function) and dementia reduced the magnitude of the effect observed (1.28, 1.03, 1.60) as well as heterogeneity ($I^2 = 78.2\%$) but did not alter our conclusion.

DISCUSSION

Our main finding from the 21 articles included in this quantitative review is that individuals with poorer pulmonary function (whether impaired function or overt respiratory disease), particularly in midlife, are at an increased risk of developing dementia in later life. Comparing the group who performed poorest on spirometry with the best performers was associated with a 1.5-fold increase in risk of dementia. The presence of a respiratory illness was associated with a similar magnitude of increased risk.

The effect size we found is comparable to other accepted risk factors for dementia as reported in comprehensive meta-analyses in the World Alzheimer Report 2014(31) (**Figure 3**) where lower educational attainment, for example, was found to be associated with an 1.8-fold increased risk of incident dementia (effect estimate combining adjusted odds ratios and HRs, 95% CI 1.83, 1.63-2.05; 31 studies). Pooling 31 studies revealed that depression was associated with around a doubling in the risk of incident dementia (unadjusted effect estimate, 1.97, 95% CI 1.67-2.02) relative to people who were free of this psychological disorder, and having diabetes in late life was associated with a 1.5-fold increase in the risk of developing dementia of any type (1.50, 1.33-1.70) and a doubling of risk of developing vascular dementia (2.39, 1.92-2.98). The recent Lancet commission on dementia prevention, intervention and care similarly reported approximately 1.5-

fold increased relative risk of dementia for individuals with midlife obesity, hypertension or later life smoking (**Figure 3**).⁽³²⁾

We note a recent systematic review of four longitudinal studies on the association between pulmonary function and cognitive performance.⁽³³⁾ While critical of the methodological quality of the studies they included, the investigators found a cross-sectional association between poorer lung function and lower levels of cognitive function, but little evidence for a longitudinal association. This may reflect different mechanisms of cognitive performance and neurological pathology underlying dementia as seems to be the case with other risk factors, such as vitamin D levels.^(34, 35)

Limitations and strengths

The comprehensive search strategy used is likely to have identified practically all relevant published studies and the inclusion of only longitudinal studies strengthens the robustness of our conclusions since, while such studies still only describe associations and do not permit causal inferences to be drawn, the temporal association between exposure and outcome adds weight to the potential importance of any identified association. The pooling of results, where possible, in random effects meta-analyses provides a quantitative summary of the evidence being a more precise estimate and overview of the literature than narrating the results of the individual studies.

There are several limitations to our work. The substantial statistical heterogeneity between studies is matched by methodological heterogeneity and – importantly – variation in the specific measure of pulmonary function used. This limited the number of studies which could be pooled in meta-analyses which may have biased our results, though the direction of bias is unlikely to be consistent in all the excluded studies.

The methodology used for dementia ascertainment is a potentially important limitation for individual studies. Face-to-face assessment by a clinician combined with brain imaging is a robust method to ascertain incident dementia cases, but is resource-intensive and differential participation in the screening process by different groups can introduce bias.(36) Linkage to electronic medical records has been shown to identify only part of a known cohort of people with dementia, particularly if multiple sources are used, although mild and undiagnosed cases are not captured.(14, 37) Death certification has been criticised as a methodology for identifying dementia cases but reporting of dementia on death certificates seems to be becoming increasingly comprehensive: for instance, a recent investigation found that, in a memory clinic cohort, of all the patients with diagnosed dementia who died during the follow-up, death certification correctly identified the diagnosis in as large a proportion as 70% of deceased patients.(38) Furthermore, investigators studying BMI and dementia found their results were similar whether dementia was ascertained solely from mortality data or whether other methods were also used.(39)

Plausible mechanisms

A number of lines of research, in combination with the disappointing results from preventive interventions of dementia implemented at older ages,(40, 41) provide circumstantial support for aetiological process acting from across the life course.(42-46) First, recent diagnostic criteria for Alzheimer disease acknowledge a long induction period for dementia such that an asymptomatic ‘preclinical’ phase is now part of the classification.(47) Second, this accords with findings from pathological and epidemiological studies suggesting that dementia has its origins earlier in life than previously thought. For example, autopsy studies of individuals of all ages demonstrate that Alzheimer-type pathology begins to develop decades before the clinical onset of symptoms.(48-50) Third, among persons without dementia, measurements of the Alzheimer biomarker, cerebral amyloid pathology suggest a 20- to 30-year interval between first development of

amyloid positivity and onset of clinical dementia.(51) Fourth, there is some evidence from prospective cohort studies that cardiovascular disease risk factors measured in midlife are associated with later dementia risk.(10, 30, 52-54) For example, in a recent analysis of the Atherosclerosis Risk in Communities (ARIC) study, midlife hypertension and elevated midlife systolic blood pressure predicted accelerated cognitive decline during 20 years of follow-up.(55) That cardiovascular disease risk factors ‘track’ from early life into adulthood(56, 57) – for example, there is a correlation between blood pressure measured in childhood and again later in life(58) – is consistent with the long-term influence of exposures occurring in childhood. Fifth, a recent observational study linked *early* life cardiorespiratory fitness with later young-onset dementia,(59) though a similar association was not observed between cardiovascular disease risk factors and late-onset dementia mortality elsewhere.(60)

There are at least three plausible mechanisms for the observed association: (i) hypoxic damage to the brain resulting from poorer pulmonary function; (ii) pulmonary function may serve as a proxy for other exposures earlier in the life course which increase dementia risk; and (iii) the association may result from the shared aetiology between pulmonary, cardiovascular disease and dementia. These mechanisms will now be considered in turn.

First, the hypoxia theory proposes that poor pulmonary function is not only a risk marker but also a possible risk factor for dementia through its effects on the brain’s oxygen supply. Indeed, most dementia cases in old age are with mixed pathologies including both vascular and neuronal damage. For example, the hippocampus – an area of the brain selectively affected in Alzheimer’s disease – is particularly vulnerable to ischaemic damage,(61) although animal models of chronic hypoperfusion demonstrate impairment of spatial working memory and slowly evolving white matter abnormalities but no neuropathological changes in the hippocampus.(62) Future analyses of magnetic resonance imaging in large prospective cohort studies, such as UK Biobank(63) or

the European Prevention of Alzheimer’s Disease (EPAD) Longitudinal Cohort Study(64) could help interrogate more closely the putative influence of hypoxia on the hippocampus and other areas of the brain.

Second, similarly to physical stature with which it is correlated, lung function may reflect life course exposures which modify an individual’s risk of dementia.(6, 44, 65, 66) As alluded to above, the life course paradigm in epidemiology hypothesises that exposures at different points in the life course could influence the risk of developing dementia, either through an accumulation of risk or through exposure at critical/sensitive periods.(44-46) Researchers from the Age, Gene/Environment Susceptibility study in Reykjavik, Iceland, for example, reported that smaller birth size (considered a measure of intrauterine experience) was related to poorer cognitive function at the age of 75, providing the first evidence that even the time before birth is relevant to cognitive ageing.(67) Other mechanisms includes: impaired growth leading to reduced maximal lung function; exposure to environmental factors affecting lung function and development, such as tobacco smoke (direct or indirect);(68) illness, such as childhood lower respiratory tract infections(69) and airway hyperresponsiveness;(70) socioeconomic factors (poverty, educational failure, and less-advantaged social class,(71-77); environmental factors affecting lung function, such as atmospheric pollution(72) and local exposure to traffic.(78, 79)

Third, both Alzheimer’s disease and vascular dementia may share some aetiology with cardiovascular disease and this overlap in the conditions might explain the association, independent of smoking.(80-82) It has been hypothesised that oxidative stress, inflammation, and amyloid deposition may link these two important conditions.(83, 84) In particular, oxidative stress and synaptic dysfunction appear to be closely linked(85) and brain ischaemia – which could result from cerebral atherosclerosis and stroke – causes oxidative stress-mediated

damage.⁽⁸⁶⁾ This may possibly be exacerbated by the pro-inflammatory function of *APOE*, but this effect is controversial.⁽⁸⁷⁾ ⁽⁸⁸⁾

Clinical and public health implications

In terms of prevention, the possibility that the association between pulmonary function and cognition might reflect a cause-and-effect relation is particularly important. To date, however, plausible mechanisms linking pulmonary function to dementia include both causal and non-causal explanations and further research on this issue is therefore needed.⁽⁹⁾

The point in time at which risk factors are measured seems to be important for their ability, or lack of it, to predict later dementia or cognitive decline: There was some evidence of an age-dependent association with stronger links seen for midlife than old age respiratory function and respiratory disease. Further research is needed to clarify whether this reflects the longer exposure period among younger individuals or a critical period in which poor respiratory function is particularly damaging.

Future directions

Pulmonary function alone is likely to have relatively low sensitivity and specificity as a predictor of cognitive decline and dementia and therefore may not be a useful predictor of dementia in the absence of a range of other predictive factors. Further research is needed to examine this. One way forward is examination of pulmonary function and pathology as a contributor to risk factor algorithms – such as the modified CAIDE risk score⁽⁵⁴⁾ – given the reported associations between pulmonary function and dementia which remained after adjustment for cardiovascular risk factors. To date, there is some evidence to suggest that such risk scores predict cognitive function⁽⁸⁹⁾ and decline,⁽⁹⁰⁾ although there is less evidence for prediction of dementia.⁽⁹¹⁾

Therefore there is, as yet, no risk score including lung function which can be used in clinical practice.

In addition to risk stratification and early identification of risk groups, further work is also required to confirm or refute the importance of pulmonary function as a risk factor amenable to modification and thus a target for prevention. Extended follow up of studies where the initial focus was treating respiratory illness might be a pragmatic place to start. It would be difficult to conduct a powered randomised, controlled trial on this topic given the long follow-up from mid-life into later life needed and the large sample size required to obtain a sufficient number of incident dementia cases. Therefore, in order to reduce confounding and reverse causation bias, Mendelian randomization studies with genetic variants related to lung function as an instrument would provide one avenue to pursue.

Further mechanistic research is also warranted in order to test in depth plausible pathways linking pulmonary function and dementia, such as the hypoxia and vascular damage hypotheses. The global public health importance of dementia is such that researchers should pursue this promising line of research on pulmonary function.

FUNDING & ACKNOWLEDGEMENTS

TCR was supported by the Alzheimer Scotland Marjorie MacBeath fellowship from 2015-16 and is now employed in the UK National Health Service. TCR and GDB are members of both the Alzheimer Scotland Dementia Research Centre funded by Alzheimer Scotland and the University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative. MK is supported by the Medical Research Council, UK (S011676, R024227), NordForsk, the Nordic Research Programme on Health and Welfare (grant #75021), the Academy of Finland (311492), and the Helsinki Institute of Life Science. All researchers are independent of funders.

The authors have no conflicts of interest.

These results were presented in preliminary form as a poster at the AAIC 2017.

FINANCIAL DISCLOSURES

This work was unfunded. The authors have no conflicts of interest to disclose.

REFERENCES

1. Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. Alzheimer's Disease International, 2015.
2. Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. *Lancet* (London, England). 2013; 382(9902): 1405-12.
3. Qiu C, von Strauss E, Bäckman L, Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. *Neurology*. 2013; 80(20): 1888-94.
4. Matthews F, Stephan B, Robinson L, Jagger C, Barnes L, Arthur A, et al. A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. *Nature Communications*. 2016; 7.
5. Prince M, Guerchet M, Prina M, Alzheimer's Disease International. Policy Brief for Heads of Government: The Global Impact of Dementia 2013–2050. Alzheimer Disease International, 2013.
6. Batty GD, Gunnell D, Langenberg C, Smith GD, Marmot MG, Shipley MJ. Adult height and lung function as markers of life course exposures: associations with risk factors and cause-specific mortality. *Eur J Epidemiol*. 2006; 21(11): 795-801.
7. Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. *Int J Epidemiol*. 2002; 31(2): 285-93.
8. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS med*. 2009; 6(7): e1000097.
9. Guo X, Waern M, Sjögren K, Lissner L, Bengtsson C, Björkelund C, et al. Midlife respiratory function and Incidence of Alzheimer's disease: A 29-year longitudinal study in women. *Neurobiol Aging*. 2007; 28(3): 343-50.
10. Alonso A, Jacobs Jr DR, Menotti A, Nissinen A, Dontas A, Kafatos A, et al. Cardiovascular risk factors and dementia mortality: 40 years of follow-up in the Seven Countries Study. *J Neurol Sci*. 2009; 280(1): 79-83.
11. Giltay EJ, Nissinen A, Giampaoli S, Kromhout D. Apolipoprotein E genotype modifies the association between midlife lung function and cognitive function in old age. *Dement Geriatr Cogn*. 2009; 28(5): 433-41.
12. Pathan SS, Gottesman RF, Mosley TH, Knopman DS, Sharrett AR, Alonso A. Association of lung function with cognitive decline and dementia: the Atherosclerosis Risk in Communities (ARIC) Study. *Eur J Neurol*. 2011; 18(6): 888-98.
13. Vidal JS, Aspelund T, Jonsdottir MK, Jonsson PV, Harris TB, Lopez OL, et al. Pulmonary function impairment may be an early risk factor for late-life cognitive impairment. *Journal of the American Geriatrics Society*. 2013; 61(1): 79-83.
14. Russ TC, Starr JM, Stamatakis E, Kivimäki M, Batty GD. Pulmonary function as a risk factor for dementia death: an individual participant meta-analysis of six UK general population cohort studies. *Journal of Epidemiology and Community Health*. 2015; 69: 550-6.
15. Gilsanz P, Mayeda ER, Flatt J, Glymour MM, Quesenberry CP, Jr., Whitmer RA. Early Midlife Pulmonary Function and Dementia Risk. *Alzheimer disease and associated disorders*. 2018.
16. Lutsey PL, Chen N, Mirabelli MC, Lakshminarayanan K, Knopman DS, Vossell KA, et al. Impaired Lung Function, Lung Disease and Risk of Incident Dementia. *American journal of respiratory and critical care medicine*. In press.
17. Simons LA, Simons J, McCallum J, Friedlander Y. Lifestyle factors and risk of dementia: Dubbo Study of the elderly. *The Medical journal of Australia*. 2006; 184(2): 68-70.

18. Newman AB, Sachs MC, Arnold AM, Fried LP, Kronmal R, Cushman M, et al. Total and cause-specific mortality in the cardiovascular health study. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2009; 64(12): 1251-61.
19. Sibbett RA, Russ TC, Allerhand M, Deary IJ, Starr JM. Physical fitness and dementia risk in the very old: a study of the Lothian Birth Cohort 1921. *BMC psychiatry*. 2018; 18(1): 285.
20. Defina LF, Willis BL, Radford NB, Gao A, Leonard D, Haskell WL, et al. The association between midlife cardiorespiratory fitness levels and later-life dementia: a cohort study. *Annals of internal medicine*. 2013; 158(3): 162-8.
21. Liao KM, Ho CH, Ko SC, Li CY. Increased Risk of Dementia in Patients With Chronic Obstructive Pulmonary Disease. *Medicine*. 2015; 94(23): e930.
22. Liao WC, Lin CL, Chang SN, Tu CY, Kao CH. The association between chronic obstructive pulmonary disease and dementia: a population-based retrospective cohort study. *European journal of neurology*. 2015; 22(2): 334-40.
23. Minami Y, Tsuji I, Fukao A, Hisamichi S, Asano H, Sato M, et al. Physical status and dementia risk: a three-year prospective study in urban Japan. *The International journal of social psychiatry*. 1995; 41(1): 47-54.
24. Shah FA, Pike F, Alvarez K, Angus D, Newman AB, Lopez O, et al. Bidirectional relationship between cognitive function and pneumonia. *American journal of respiratory and critical care medicine*. 2013; 188(5): 586-92.
25. Yeh JJ, Wei YF, Lin CL, Hsu WH. Effect of the asthma-chronic obstructive pulmonary disease syndrome on the stroke, Parkinson's disease, and dementia: a national cohort study. *Oncotarget*. 2018; 9(15): 12418-31.
26. Xie F, Xie L. COPD and the risk of mild cognitive impairment and dementia: a cohort study based on the Chinese Longitudinal Health Longevity Survey. *International journal of chronic obstructive pulmonary disease*. 2019; 14: 403-8.
27. Chen MH, Li CT, Tsai CF, Lin WC, Chang WH, Chen TJ, et al. Risk of dementia among patients with asthma: a nationwide longitudinal study. *Journal of the American Medical Directors Association*. 2014; 15(10): 763-7.
28. Peng YH, Wu BR, Su CH, Liao WC, Muo CH, Hsia TC, et al. Adult asthma increases dementia risk: a nationwide cohort study. *Journal of epidemiology and community health*. 2015; 69(2): 123-8.
29. Eriksson UK, Gatz M, Dickman PW, Fratiglioni L, Pedersen NL. Asthma, eczema, rhinitis and the risk for dementia. *Dementia and geriatric cognitive disorders*. 2008; 25(2): 148-56.
30. Rusanen M, Ngandu T, Laatikainen T, Tuomilehto J, Soininen H, Kivipelto M. Chronic obstructive pulmonary disease and asthma and the risk of mild cognitive impairment and dementia: a population based CAIDE study. *Current Alzheimer research*. 2013; 10(5): 549-55.
31. Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer Report 2014: Dementia and Risk Reduction - an analysis and protective and modifiable factors. *Alzheimer's Disease International*, 2014.
32. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. *Lancet (London, England)*. 2017; 390(10113): 2673-734.
33. Duggan EC, Graham RB, Piccinin AM, Jenkins ND, Clouston S, Muniz Terrera G, et al. A Systematic Review of Pulmonary Function and Cognition in Aging. *The Journals of Gerontology: Series B*. 2018: gby128-gby.
34. Mokry LE, Ross S, Morris JA, Manousaki D, Forgetta V, Richards JB. Genetically decreased vitamin D and risk of Alzheimer disease. *Neurology*. 2016; 87(24): 2567-74.
35. Maddock J, Zhou A, Cavadino A, Kuzma E, Bao Y, Smart MC, et al. Vitamin D and cognitive function: A Mendelian randomisation study. *Scientific reports*. 2017; 7(1): 13230.

36. Bermejo F, Gabriel R, Vega S, Morales JM, Rocca WA, Anderson DW. Problems and Issues with Door-To-Door, Two-Phase Surveys: An Illustration from Central Spain. *Neuroepidemiology*. 2001; 20(4): 225-31.
37. Russ TC, Gatz M, Pedersen NL, Hannah J, Wyper G, Batty GD, et al. Geographical variation in dementia: examining the role of environmental factors in Sweden and Scotland. *Epidemiology (Cambridge, Mass)*. 2015; 26(2): 263-70.
38. Russ TC, Batty GD, Starr JM. Cognitive and behavioural predictors of survival in Alzheimer disease: results from a sample of treated patients in a tertiary-referral memory clinic. *International Journal of Geriatric Psychiatry*. 2012; 27(8): 844-53.
39. Kivimäki M, Luukkonen R, Batty GD, Ferrie JE, Pentti J, Nyberg ST, et al. Body mass index and risk of dementia: Analysis of individual-level data from 1.3 million individuals. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2018; 14(5): 601-9.
40. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. *Cochrane Database of Systematic Reviews*. 2009; 2: CD003160.
41. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. *Cochrane Database Syst Rev*. 2009; 4: CD004034.
42. Kuh D, Ben-Shlomo Y, Lynch J, Hallqvist J, Power C. Life course epidemiology. *Journal of Epidemiology and Community Health*. 2003; 57(10): 778.
43. Ben-Shlomo Y, Mishra G, Kuh D. Life Course Epidemiology. In: *Handbook of Epidemiology* (eds W Ahrens, I Pigeot): 1521-49. Springer New York, 2014.
44. Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. *International Journal of Epidemiology*. 2002; 31(2): 285-93.
45. Kuh D, Shlomo YB. *A life course approach to chronic disease epidemiology*. Oxford University Press, 2004.
46. Whalley LJ, Dick FD, McNeill G. A life-course approach to the aetiology of late-onset dementias. *Lancet Neurology*. 2006; 5(1): 87-96.
47. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*. 2011; 7(3): 280-92.
48. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathologica*. 1991; 82(4): 239-59.
49. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiology of Aging*. 1997; 18(4): 351-7.
50. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years. *Journal of Neuropathology & Experimental Neurology*. 2011; 70(11): 960-9.
51. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *Jama*. 2015; 313(19): 1924-38.
52. Whitmer R, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology*. 2005; 64(2): 277-81.
53. Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES, Cox NJ, et al. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. *Ann Intern Med*. 2010; 153(3): 176-81.
54. Exalto LG, Quesenberry CP, Barnes D, Kivipelto M, Biessels GJ, Whitmer RA. Midlife risk score for the prediction of dementia four decades later. *Alzheimers Dement*. 2013; ePub.

55. Gottesman RF, Schneider AL, Albert M, Alonso A, Bandeen-Roche K, Coker L, et al. Midlife Hypertension and 20-Year Cognitive Change: The Atherosclerosis Risk in Communities Neurocognitive Study. *JAMA Neurology*. 2014; 71(10): 1218-27.
56. Webber LS, Freedman DS, Cresanta JL. Tracking of cardiovascular disease risk factor variables in school-age children. In: *Causation of cardiovascular risk factors in children* (ed GS Berenson): 42-64. Raven Press, 1986.
57. Strasser T. Prevention in childhood of major cardiovascular diseases of adults. In: *Prevention in childhood of health problems in adult life* (ed F Falkner). World Health Organisation, 1980.
58. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood a systematic review and meta-regression analysis. *Circulation*. 2008; 117(25): 3171-80.
59. Nyberg J, Åberg MAI, Schiöler L, Nilsson M, Wallin A, Torén K, et al. Cardiovascular and cognitive fitness at age 18 and risk of early-onset dementia. *Brain*. 2014; 137: 1514-23.
60. Batty GD, Galobardes B, Starr JM, Jeffreys M, Davey Smith G, Russ TC. Examining if being overweight really confers protection against dementia: Sixty-four year follow-up of participants in the Glasgow University alumni cohort study. *Journal of negative results in biomedicine*. 2016; 15(1): 19.
61. Hatanpää KJ, Räsänen JM, Herndon E, Burns DK, Foong C, Habib AA, et al. Hippocampal sclerosis in dementia, epilepsy, and ischemic injury: differential vulnerability of hippocampal subfields. *Journal of Neuropathology and Experimental Neurology*. 2014; 73(2): 136-42.
62. Kitamura A, Saito S, Maki T, Oishi N, Ayaki T, Hattori Y, et al. Gradual cerebral hypoperfusion in spontaneously hypertensive rats induces slowly evolving white matter abnormalities and impairs working memory. *Journal of Cerebral Blood Flow & Metabolism*. 2016; 36(9): 1592-602.
63. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine*. 2015; 12(3): e1001779.
64. Ritchie CW, Molinuevo JL, Truyen L, Satlin A, van der Geyten S, Lovestone S, et al. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. *Lancet Psychiatry*. 2015; 3(2): 179-86.
65. Beerli MS, Davidson M, Silverman JM, Noy S, Schmeidler J, Goldbourt U. Relationship between body height and dementia. *Am J Geriatr Psychiatry*. 2005; 13(2): 116-23.
66. Russ TC, Kivimäki M, Starr JM, Stamatakis E, Batty GD. Height in Relation to Dementia Death: Individual-participant Meta-analysis of Eighteen UK Prospective Cohort Studies. *British Journal of Psychiatry*. 2014; 205: 348-54.
67. Muller M, Sigurdsson S, Kjartansson O, Jonsson PV, Garcia M, von Bonsdorff MB, et al. Birth size and brain function 75 years later. *Pediatrics*. 2014; 134(4): 761-70.
68. Cook DG, Strachan DP, Carey IM. Parental smoking and spirometric indices in children. *Thorax*. 1998; 53(10): 884-93.
69. Tennant PWG, Gibson GJ, Pearce MS. Lifecourse predictors of adult respiratory function: results from the Newcastle Thousand Families Study. *Thorax*. 2008; 63(9): 823-30.
70. Harmsen L, Ulrik CS, Porsbjerg C, Thomsen SF, Holst C, Backer V. Airway hyperresponsiveness and development of lung function in adolescence and adulthood. *Respiratory medicine*. 2014; 108(5): 752-7.
71. Bartley M, Kelly Y, Sacker A. Early life financial adversity and respiratory function in midlife: a prospective birth cohort study. *American journal of epidemiology*. 2012; 175(1): 33-42.
72. Mann SL, Wadsworth ME, Colley JR. Accumulation of factors influencing respiratory illness in members of a national birth cohort and their offspring. *Journal of Epidemiology and Community Health*. 1992; 46(3): 286-92.

73. Lawlor DA, Ebrahim S, Davey Smith G. Association between self-reported childhood socioeconomic position and adult lung function: findings from the British Women's Heart and Health Study. *Thorax*. 2004; 59(3): 199-203.
74. Tabak C, Spijkerman AMW, Verschuren WMM, Smit HA. Does educational level influence lung function decline (Doetinchem Cohort Study)? *European Respiratory Journal*. 2009; 34(4): 940-7.
75. Johannessen A, Eagan TML, Omenaas ER, Bakke PS, Gulsvik A. Socioeconomic risk factors for lung function decline in a general population. *European Respiratory Journal*. 2010; 36(3): 480-7.
76. Jackson B, Kubzansky LD, Cohen S, Weiss S, Wright RJ. A matter of life and breath: childhood socioeconomic status is related to young adult pulmonary function in the CARDIA study. *International Journal of Epidemiology*. 2004; 33(2): 271-8.
77. Ramsay SE, Whincup PH, Lennon LT, Morris RW, Wannamethee SG. Longitudinal associations of socioeconomic position in childhood and adulthood with decline in lung function over 20 years: results from a population-based cohort of British men. *Thorax*. 2011; 66(12): 1058-64.
78. Gauderman WJ, Vora H, McConnell R, Berhane K, Gilliland F, Thomas D, et al. Effect of exposure to traffic on lung development from 10 to 18 years of age: a cohort study. *Lancet* (London, England). 369(9561): 571-7.
79. Götschi T, Heinrich J, Sunyer J, Künzli N. Long-Term Effects of Ambient Air Pollution on Lung Function: A Review. *Epidemiology* (Cambridge, Mass). 2008; 19(5): 690-701
10.1097/EDE.0b013e318181650f.
80. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia aging study. *Annals of Neurology*. 2002; 52(2): 168-74.
81. Sin DD, Wu LL, Man SFP. The Relationship Between Reduced Lung Function and Cardiovascular Mortality: A Population-Based Study and a Systematic Review of the Literature. *Chest*. 2005; 127(6): 1952-9.
82. Stephan BC, Brayne C. Vascular factors and prevention of dementia. *International Review of Psychiatry*. 2008; 20(4): 344-56.
83. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. *The Lancet Neurology*. 2016; 15(5): 455-532.
84. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-Brain Barrier: From Physiology to Disease and Back. *Physiological Reviews*. 2019; 99(1): 21-78.
85. Tonnesen E, Trushina E. Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease. *J Alzheimers Dis*. 2017; 57(4): 1105-21.
86. Love S. Oxidative Stress in Brain Ischemia. *Brain Pathology*. 1999; 9(1): 119-31.
87. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. *Molecular nutrition & food research*. 2008; 52(1): 131-45.
88. Guo L, LaDu MJ, Van Eldik LJ. A dual role for apolipoprotein E in neuroinflammation. *Journal of Molecular Neuroscience*. 2004; 23(3): 205-12.
89. Kaffashian S, Dugravot A, Nabi H, Batty GD, Brunner E, Kivimäki M, et al. Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study. *European Heart Journal*. 2011: ehr133.
90. Kaffashian S, Dugravot A, Elbaz A, Shipley MJ, Sabia S, Kivimäki M, et al. Predicting cognitive decline A dementia risk score vs the Framingham vascular risk scores. *Neurology*. 2013; 80(14): 1300-6.
91. Russ TC, Hamer M, Stamatakis E, Starr JM, Batty GD, Kivimäki M. Does the Framingham cardiovascular disease risk score also have predictive utility for dementia death? An

individual participant meta-analysis of 11,887 men and women. *Atherosclerosis*. 2013; 228(1): 256-8.

Figure 1. PRISMA flowchart

Figure 2. The relation of forced expiratory volume and respiratory illness with dementia — meta-analysed results

Figure 3. Comparison of meta-analytic findings with accepted risk factors for dementia in the World Alzheimer Report 2014(31) and Lancet Commission on dementia prevention, intervention, and care(32)

Table 1. Summary of longitudinal studies of the association between pulmonary function and dementia

Study	Number of participants	Number of dementia cases	Measurement of pulmonary function	Age at which pulmonary function was measured <i>Mean (SD)</i> [Range]	Follow up	Findings	Risk of Bias
Lutsey et al. (2018)(16)	14,184 (5889 assessed clinically) male and female participants in the Atherosclerosis Risk in Communities (ARIC) study	1407 people developed dementia, identified by clinical assessment (N=298) and diagnostic codes recorded on hospitalisation.	FEV ₁ and FVC expressed as a percentage of age-, race-, and sex-specific predicted values	54.2 (5.8) [45-64]	Median 23.0 years Max. 27.1 years	N=14,184: Maximally-adjusted OR Q ₁ FEV ₁ (low) vs Q ₄ (high) 1.09 (95% CI 0.73, 1.65), Q ₂ 0.77 (0.50, 1.18), Q ₃ 0.90 (0.61, 1.33). OR per SD change in FEV ₁ 1.03 (0.89, 1.20). N=5889: Weighted, maximally-adjusted HR Q ₁ FEV ₁ (low) vs Q ₅ (high) 1.11 (0.93, 1.32). OR per SD change in FEV ₁ 1.05 (0.98, 1.11) Results for FVC in both sets of analyses were similar.	Low
Gilsanz et al. (2018)(15)	27,387 men and women who were members of Kaiser Permanente Northern California	7519 dementia diagnoses ascertained from inpatient and outpatient electronic medical records	FEV ₁ , FEV ₂ , and VC	41.8 (4.2) [35-50]	28+ years	Multivariable adjusted HR per litre decrease in FEV ₁ 1.13 (95% CI 1.09, 1.18). Dose response association observed – worst FEV ₁ quintile compared to best HR 1.24 (95% CI 1.14, 1.34). Results for FEV ₂ and VC similar, as were results stratified by smoking status.	Mod.
Sibbitt et al. (2018)(19)	484 men and women born in 1921 forming the Lothian Birth Cohort 1921	106 diagnoses of dementia obtained from clinical reviews, death certificates, and electronic medical records and adjudicated by a clinical panel	FEV ₁	79.04 (0.55) [Narrow age cohort]	16 years	FEV ₁ measured at age 79 years was not associated with developing dementia (multivariable-adjusted HR 1.30, 95% CI 0.74, 2.30)	Low
Russ et al. (2015)(14)	54,671 men and women from six UK cohort studies	459 dementia deaths identified from death certificates	FEV ₁ , FVC and PEF	46.8 (17.6) [16-100]	Mean (SD) 11.7 (3.7) years	There was a dose-response association between poorer lung function and a higher risk of dementia-related death. Controlling for height, socioeconomic status, smoking, and general health attenuated but did not remove the association (multivariable-adjusted HR compared to highest quartile of FEV ₁ , 95% CI: second quartile 1.15, 0.82-1.62; third quartile 1.37, 0.96-1.94; fourth quartile 2.09, 1.17-3.71).	Mod.
Alonso et al. (2009)(10)	10,211 men from 13 cohort studies of the Seven Countries Study (Finland, Greece, Italy, the Netherlands, Serbia and Croatia [formerly Yugoslavia], Japan and the USA) aged 40-59 at baseline	160 dementia deaths identified from death certificates (up to four codes were examined)	FVC (categorised into quartiles because of measurement differences between studies)	49.2 (5.6) [40-59]	40 years	Participants with poorer FVC (lowest quartile vs highest quartile) were at a lower risk of dementia death (0.54, 0.30-0.98) but there was no evidence of a dose-response association ($P_{trend}=0.28$)	Mod.
Newman et al. (2009)(18)	6575 men and women aged ≥65 years at baseline in the Cardiovascular Health Cohort Study.	392 dementia deaths identified from death certificates	FVC	72.8 (5.6) [65+]	Average 13 or 16 years for two waves of recruitment	Increasing FVC was associated with a lower risk of dementia death compared to the lowest group (<2.06L): 2.06-2.54L HR, 95% CI 0.92, 0.67-1.28; 2.54-3L 0.98, 0.69-1.40; 3-3.6L 0.79, 0.52-1.20; >3.6L 0.71, 0.44-1.15.	Mod.
Giltay et al. (2009)(11)	646 men from three cohorts of the Seven Countries Study, aged 45-64, from Finland and Italy	159 with questionable-to-mild dementia and 24 with moderate-to-severe dementia, based on the CDR for those who scored <27 on the MMSE	FEV _{0.75} and FVC	84- 50.9 (4.4) 84+ 51.4 (4.6) [45-64]	25 years	Increasing pulmonary function was associated with a decreased risk of dementia both in <i>APOE</i> ε4 non-carriers (OR moderate-to-severe dementia, 95% CI 0.43, 0.24–0.76 [FEV _{0.75}]; 0.59, 0.32–1.08 [FVC]) but an increased risk of dementia in <i>APOE</i> ε4 carriers (OR questionable-to-severe dementia, 95% CI 1.57, 0.87–2.85 [FEV _{0.75}]; 1.59, 0.91–2.77 [FVC]; $P_{interaction}<0.05$)	Mod.
Pathan et al. (2011)(12)	9837 men and women, aged 45-64 in 1987-9, who attended in the second visit (1990-2) of the ARIC study in four areas of the USA for whom hospitalisation data were available	205 hospital admissions where dementia was recorded	FEV ₁ and FVC	Q ₁ 59.1 (5.5) Q ₄ 54.1 (4.8) [47-70]	Median 14.1 years	Being in the lowest quartile compared to the highest quartile of FEV ₁ (1.6, 0.9-2.3) and FVC (2.1, 1.2-3.7) was associated with dementia hospitalisation but the FEV ₁ /FVC ratio was not. The authors conclude that a restrictive ventilatory pattern is associated with dementia, rather than obstructive or mixed patterns	Mod.
Vidal et al. (2013)(13)	3665 men and women from the AGES-RS, born between 1907 and 1935 (mean [SD] age 52.3 [5.3] at baseline)	288 cases of dementia based on cognitive screening, neuropsychological testing, informant interview, and neurological assessment. 128 people were identified to have mild cognitive impairment	FEV ₁ /height ²	Q ₁ 54.2 (5.6) Q ₄ 49.7 (5.2) [<70]	23 years	Increasing pulmonary function was associated with a decreased risk of dementia (OR, 95% CI 0.68, 0.55-0.84)	Low
Simons et al. (2006)(17)	2805 men and women aged ≥60 and living in the community in New South Wales, Australia	285 hospital admissions where dementia was recorded	PEF	Women 69.6 (7.3) Men 68.6 (6.7) [60+]	16 years	Decreasing PEF was associated with an increased risk of dementia (tertile 2 vs 3 [highest] HR, 95% CI 1.58, 1.13-2.21; 1 [lowest] vs 3 1.98, 1.42-2.75).	Mod.
Guo et al. (2007)(9)	1291 women, born in 1908, 1914, 1918, 1922, or 1930, participating in the Prospective Population Study of Women in Gothenburg (Sweden) followed from 1974 to 2003	147 dementia cases (96 AD) diagnosed clinically by neuropsychiatric examination and informant interview	PEF (in 1974-5), FEV ₁ and FVC (in 1980-1)	52 (6) [PEF 44-66 FVC/FEV ₁ 50-72]	29,739 person-years	There was an association between better pulmonary function and a lower risk of dementia (HR per SD increase [advantage] in PEF, 95% CI 0.77, 0.65-0.91; FEV ₁ 0.75, 0.59-0.95; FVC 0.72, 0.57-0.92). Similar patterns were observed for AD	Low

AD = Alzheimer's disease; AGES-RS = Age, Gene/Environment Susceptibility – Reykjavik Study; CI = confidence interval;

FEV = Forced Expiratory Volume in a specified period; (F)VVC = (Forced) Vital Capacity; HR = hazard ratio; MCI = mild cognitive impairment; OR = odds ratio;

PEF = Peak Expiratory Flow; SD = standard deviation

Table 2. Summary of longitudinal studies of the association between respiratory disease and dementia

Study	Number of participants	Number of dementia cases	Respiratory disease	Age at which disease ascertained <i>Mean (SD)</i> <i>[Range]</i>	Follow up	Findings	Risk of Bias
Xie et al. (2019)(26)	4735 participants in the Chinese Longitudinal Health Longevity Survey (CLHLS)	83 people were newly identified as having dementia, presumably based on MMSE score	Self-reported COPD diagnosis	82.9 (9.74)	3 years	Maximally-adjusted HR COPD vs no COPD 1.90 (1.08–3.33). In current smokers, the same HR was 3.38 (1.09–10.5).	High
Lutsey et al. (2018)(16)	14,184 (5889 assessed clinically) male and female participants in the Atherosclerosis Risk in Communities (ARIC) study	1407 people developed dementia, identified by clinical assessment (N=298) and diagnostic codes recorded on hospitalisation.	Participants were divided into four groups based on self-reported information and spirometry: normal, respiratory symptoms with normal spirometry, restrictive impairment pattern, and COPD	54.2 (5.8) [45-64]	Median 23.0 years Max. 27.1 years	N=14,184: Maximally-adjusted HR COPD vs normal 1.08 (95% CI 0.92, 1.27) N=5889: Weighted, maximally-adjusted OR COPD vs normal 1.16 (95% CI 0.74, 1.82)	Low
Yeh et al. (2018)(25)	30,773 men and women from the Taiwanese National Health Insurance Research Database	1920 diagnoses of dementia	>2 clinical contacts recording asthma-COPD	Asthma-COPD 65.6 (11.8) No illness 65.5 (11.9)	10 years	Asthma-COPD was associated with an increased risk of subsequent dementia (multivariable-adjusted HR 1.43, 95% CI 1.29, 1.59)	Mod.
Peng et al. (2015)(28)	12,771 people with asthma and 51,084 matched controls.	2337 individuals identified from the Taiwan National Health Insurance database.	New diagnoses of asthma recorded on the National Health Insurance database.	Asthma 53.8 (17.3) No illness 53.7 (17.4)	11 years	Asthma was associated with an increased risk of dementia (adjusted HR, 95% CI 1.27, 1.15-1.41).	Mod.
Liao et al. (2015)(22)	20,492 men and women with COPD and 40,765 matched controls.	2553 individuals identified from the Taiwan National Health Insurance database.	New diagnoses of COPD recorded on the National Health Insurance database.	COPD 67.0 (12.5) No illness 68.2 (12.4)	Mean (SD) 6.3 (3.5) years for cases, 6.9 (3.4) for controls	COPD was associated with an increased risk of dementia (adjusted HR, 95% CI 1.27, 1.20-1.36).	Mod.
Chen et al. (2014)(27)	11,030 adults aged >45 years with asthma and 44,120 age- and sex-matched controls.	1681 individuals identified from the Taiwan National Health Insurance database.	Asthma recorded on the National Health Insurance database.	60.88 (10.39)	8.0±3.0 years	Having asthma was associated with a doubling of risk of developing dementia (adjusted HR, 95% CI 2.17, 1.87-2.52).	Mod.
Liao et al. (2015)(21)	8640 men and women ≥40 years hospitalized with COPD and 17,280 age-, sex-, and admission year-matched controls.	706 individuals with AD or Parkinson's disease identified from the Taiwan National Health Insurance database.	COPD recorded on the National Health Insurance database.	68.76 (10.74)	Not stated	COPD was associated with an increased risk of dementia (adjusted HR, 95% CI 1.74, 1.55-1.96).	Mod.
Eriksson et al. (2008)(29)	22,188 twins in the population-based Swedish Twin Registry	1332 twins had a record of dementia from hospital discharge and death certificate data.	History of atopy (asthma, eczema, or rhinitis)	52.9 [37-71]	22.6±7.7 years	History of atopy was associated with a modest increased risk of AD (HR, 95% CI 1.16, 0.98-1.37) or dementia (1.16, 1.01-1.33).	Mod.
Shah et al. (2013)(24)	5888 participants in the Cardiovascular Health Study	3602 identified by two-phase screening, including clinical assessment	Hospitalisation with pneumonia	72.8 (5.6)	10 years	Pneumonia was associated with an increased risk of later dementia (HR, 95% CI 2.24, 1.62-3.11).	Low
Minami et al. (1995)(23)	3180 people without dementia in Sendai, Japan, of whom 2461 were followed up.	105 individuals were clinically diagnosed with dementia at follow up.	Self-reported respiratory disease.	≥65 years	3 years	Respiratory disease was associated with a doubling of risk of dementia (adjusted OR, 95% CI 2.28, 1.19-4.36)	Mod.
Rusanen et al. (2013)(30)	1511 male and female participants, aged 39.2-64.1 years at baseline, followed up at either of two points (1998 and/or 2005-8) from a random sample of 2000 (at baseline: 1972, 1977, 1982 or 1987) from four cohort studies in Eastern Finland	172 identified by screening and, for those screening positive, clinical examination	Self-reported diagnosis of COPD or asthma	50.6 (6.0) [39.2-64.1]	Mean (SD) 25.5 (6.2) years	Pulmonary disease at baseline was associated with an increased risk of later dementia (HR, 95% CI 1.94, 1.16-3.27). Pulmonary disease in 1998 was associated with a decreased risk of dementia in 2005-8 (0.42, 0.19-0.93).	Mod.

AD = Alzheimer's disease; CI = confidence interval; COPD = Chronic Obstructive Pulmonary Disease; HR = hazard ratio;

IQCODE = Informant Questionnaire on Cognitive Decline in the Elderly ;

RBANS = Repeatable Battery for the Assessment of Neuropsychological Status; SD = standard deviation

Supplementary Figure 1. The association between Forced Vital Capacity – lowest quartile compared to highest quartile and one standard deviation decrease – and dementia with meta-analysed results

STUDY **N** **N dementia** **HR (95% CI)**

FVC – lowest vs highest quartiles

Pathan et al., 2011	66414	104	2.19 (0.82–5.85)
Alonso et al., 2009	10211	160	1.85 (1.02–3.35)
Newman et al., 2009	6575	392	1.41 (0.87–2.28)
Russ et al., 2015	48025	393	2.65 (1.48–4.74)
Lutsey et al., In press	14184	1407	1.06 (0.71–1.59)
Summary	145409	2456	1.63 (1.14–2.32)

FVC – 1 SD decrease

Giltay et al., 2009	358	17	1.69 (0.92–3.11)
Giltay et al., 2009	105	41	0.63 (0.36, 1.10)
Guo et al., 2007	1168	134	1.39 (1.09–1.76)
Russ et al., 2015	48025	393	1.41 (1.17–1.69)
Lutsey et al., In press	14184	1407	1.08 (0.93–1.25)
Summary	63840	1992	1.21 (0.97–1.51)

Supplementary Figure 2. The association between Peak Expiratory Flow – lowest quartile compared to highest quartile and one standard deviation decrease – and dementia with meta-analysed results